The AI trade cooled and oil sank. A closer look at Wall Street’s volatile week
Wall Street spent the week debating who the biggest winners and losers of the artificial intelligence boom will…
We’re trimming a stock into strength, raising our price target
We are selling 50 shares of Cardinal Health at roughly $235. Following the trade, Jim Cramer’s Charitable Trust…
Cardinal Health’s sell-off was an overreaction. We’d be buyers
We’ve taken a closer look at Cardinal Health’s quarterly results and conference call following Thursday’s sell-off. Our conclusion:…
The money to AI stocks is a problem, and how it can be fixed
We do not have enough money coming into this market. The funds flow only to stocks tied to…
Amazon weighs a deal to boost its satellite internet ambitions. Why it’s worthy pursuit
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET.…
We’re dipping into our large cash pile to buy more of this health-care stock
We are buying 90 shares of Cardinal Health at roughly $217. Following the trade, Jim Cramer’s Charitable Trust…
We’re initiating a position in this health-care stock with a $260 price target
Shortly after the opening bell, we will initiate a position in Cardinal Health , buying 170 shares at…
More drugs should be over-the-counter
Food and Drug Administration Commissioner Marty Makary told CNBC that he believes “everything should be over the counter”…
QCOM, MASTR, ALGM, EL and more
Check out the companies making the biggest moves in premarket trading: Qualcomm — The chipmaker sank nearly 11%…
I talked to many health CEOs out West and see big things for drug stocks
We get so caught up in the buzz and the sizzle that we forget about the steak, especially…
Health-Care Earnings Top S&P 500 on Strong Drug, Hospital Demand
The largest American public health-care companies outperformed other industries in the third quarter, as higher new and specialty…